title: [Multifocal Langerhans cell histiocytosis of bone: indications for radiotherapy].
abstract: Langerhans cell histiocytosis is a non-malignant proliferative disease of unknown etiology that can affect one or more organs. This is a rare disease, 1 to 2/100,000, affecting mainly children with a male predominance. The osseous lesions are the most frequent (60 to 90%). There is however no consensus treatment for the management of these sites. We report the cases of two patients successfully treated with radiotherapy after primary chemotherapy, at doses of 15 Gy in ten sessions of 1.5 Gy for one patient and 18 Gy in ten fractions of 1.8 Gy for the other. Single or multifocal bone Langerhans cell histiocytosis without visceral involvement is a benign, self-limiting affection in most cases. Some bone lesions could be treated by radiotherapy alone. But the high variability of doses currently given in the literature does not allow determining the lowest effective dose limiting the risk of secondary neoplasia or impaired growth in children, in whom lower doses of 6 to 8 Gy are recommended. The decision of radiotherapy must be weighed against the risk of the disease. Caution should be the rule in this non-malignant tumour pathology.
authors.affiliation: Service de radiothérapie, centre régional de lutte contre le cancer, institut Bergonié, 229, cours de l'Argonne, 33076 Bordeaux cedex, France. gaundong@yahoo.fr
authors.forename: G-L
authors.initials: GL
authors.lastname: Gaundong Mbéthé
authors.forename: C
authors.initials: C
authors.lastname: Dejean
authors.forename: B
authors.initials: B
authors.lastname: Henriques de Figueiredo
authors.forename: P
authors.initials: P
authors.lastname: Sargos
authors.forename: A
authors.initials: A
authors.lastname: Italiano
authors.forename: G
authors.initials: G
authors.lastname: Kantor
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D001847:Bone Diseases / Q000188:drug therapy / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D019583:Dose Fractionation, Radiation; D006646:Histiocytosis, Langerhans-Cell / Q000188:drug therapy / Q000532:radiotherapy*; D006801:Humans; D007085:Ilium / Q000473:pathology; D008297:Male; D008334:Mandible / Q000473:pathology; D008336:Mandibular Diseases / Q000188:drug therapy / Q000532:radiotherapy; D008875:Middle Aged; D010014:Osteolysis / Q000209:etiology; D010294:Parietal Bone / Q000473:pathology; D020266:Radiotherapy, Conformal; D012306:Risk; D013122:Spinal Diseases / Q000188:drug therapy / Q000532:radiotherapy; D013249:Sternum / Q000473:pathology; D014747:Vinblastine / Q000627:therapeutic use
chemical_list: D000305:Adrenal Cortex Hormones; D014747:Vinblastine